文献速递精神分裂症与精神病性障碍

血浆脂肪酸浓度与精神分裂症的关联:两样本孟德尔随机化研究

Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study.
PubMed 文献 · Lancet Psychiatry · 2021-11-01

该研究采用两样本孟德尔随机化方法,利用公开的脂肪酸浓度与精神分裂症全基因组关联研究汇总数据,评估omega-3和omega-6脂肪酸浓度与精神分裂症的因果关系。结果显示长链omega-3和长链omega-6脂肪酸浓度与精神分裂症风险降低相关,而短链脂肪酸的关联证据较弱。作者认为结果与长链多不饱和脂肪酸对精神分裂症的保护作用相容,需进一步研究补充长链多不饱和脂肪酸或饮食强化是否有助于预防精神分裂症发病。

要点

  • 长链omega-3和长链omega-6脂肪酸浓度与精神分裂症风险降低相关。
  • 短链omega-3和短链omega-6脂肪酸与精神分裂症风险增加的关联证据较弱。
  • 作者认为需进一步研究长链多不饱和脂肪酸补充或饮食强化是否有助于预防精神分裂症发病。

核心结论

  • 结果与长链omega-3和长链omega-6脂肪酸对精神分裂症的保护作用相容,提示精神分裂症患者可能难以将短链多不饱和脂肪酸转化为长链多不饱和脂肪酸。
  • 需进一步研究以确定补充长链多不饱和脂肪酸或饮食强化是否有助于预防精神分裂症发病。

研究设计与样本

  • 两样本孟德尔随机化研究,使用公开的去标识汇总水平数据。
  • 暴露-结局关系采用逆方差加权两样本孟德尔随机化方法评估,使用脂肪酸浓度和精神分裂症的全基因组关联研究结果。
  • 全基因组关联研究结果可用于欧洲 ancestry(脂肪酸)以及欧洲和亚洲 ancestry(精神分裂症)样本。
  • 总体年龄和性别信息无法从汇总水平全基因组关联研究结果中计算。
  • 敏感性分析采用加权中位数、加权众数和孟德尔随机化Egger回归方法。

主要发现

  • 孟德尔随机化分析表明长链omega-3和长链omega-6脂肪酸浓度与精神分裂症风险降低相关,例如二十二碳六烯酸的逆方差加权OR为0.83(95%CI 0.75-0.92)。
  • 短链omega-3和短链omega-6脂肪酸与精神分裂症风险增加的关联证据较弱,例如α-亚麻酸的逆方差加权OR为1.07(95%CI 0.98-1.18)。
  • 敏感性分析和FADS单核苷酸多态性分析结果一致,例如二十二碳六烯酸OR为0.74(95%CI 0.58-0.96),α-亚麻酸OR为1.08(95%CI 1.02-1.15)。
  • ELOVL2单核苷酸多态性分析的估计值较不精确,与每种脂肪酸指标的风险增加和保护效应均相容。
  • 多变量孟德尔随机化表明,在控制其他脂质后,二十二碳六烯酸对精神分裂症的保护效应持续存在,但证据略弱(多变量逆方差加权OR为0.84,95%CI 0.71-1.01)。

关键数值与推荐

  • 二十二碳六烯酸逆方差加权OR为0.83(95%CI 0.75-0.92),与精神分裂症风险降低相关。
  • α-亚麻酸逆方差加权OR为1.07(95%CI 0.98-1.18),与精神分裂症风险增加的关联证据较弱。
  • FADS单核苷酸多态性分析中二十二碳六烯酸OR为0.74(95%CI 0.58-0.96),α-亚麻酸OR为1.08(95%CI 1.02-1.15)。
  • 多变量逆方差加权分析中二十二碳六烯酸OR为0.84(95%CI 0.71-1.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 总体年龄和性别信息无法从汇总水平全基因组关联研究结果中计算。
  • ELOVL2单核苷酸多态性分析的估计值较不精确,与每种脂肪酸指标的风险增加和保护效应均相容。
  • 多变量孟德尔随机化中二十二碳六烯酸的保护效应证据略弱(OR 0.84,95%CI 0.71-1.01)。
  • 需进一步研究以确定补充长链多不饱和脂肪酸或饮食强化是否有助于预防精神分裂症发病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although studies suggest that concentrations of omega-3 and omega-6 fatty acids are lower in individuals with schizophrenia, evidence for beneficial effects of fatty acid supplementation is scarce. Therefore, in this study, we aimed to determine whether omega-3 and omega-6 fatty acid concentrations are causally related to schizophrenia. METHODS: We did a two-sample Mendelian randomisation study, using deidentified summary-level data that were publicly available. Exposure-outcome relationships were evaluated using the inverse variance weighted two-sample Mendelian randomisation method using results from genome-wide association studies (GWASs) of fatty acid concentrations and schizophrenia. GWAS results were available for European (fatty acids) and European and Asian (schizophrenia) ancestry samples. Overall age and gender information were not calculable from the summary-level GWAS results. Weighted median, weighted mode, and Mendelian randomisation Egger regression methods were used as sensitivity analyses. To address underlying mechanisms, further analyses were done using single instruments within the FADS gene cluster and ELOVL2 gene locus. FADS gene cluster and ELOVL2 gene causal effects on schizophrenia were calculated by dividing the single nucleotide polymorphism (SNP)-schizophrenia effect estimate by the SNP-fatty acid effect estimate with standard errors derived using the first term from a delta method expansion for the ratio estimate. Multivariable Mendelian randomisation was used to estimate direct effects of omega-3 fatty acids on schizophrenia, independent of omega-6 fatty acids, lipoproteins (ie, HDL and LDL), and triglycerides. FINDINGS: Mendelian randomisation analyses indicated that long-chain omega-3 and long-chain omega-6 fatty acid concentrations were associated with a lower risk of schizophrenia (eg, inverse variance weighted odds ratio [OR] 0·83 [95% CI 0·75-0·92] for docosahexaenoic acid). By contrast, there was weak evidence that short-chain omega-3 and short-chain omega-6 fatty acids were associated with an increased risk of schizophrenia (eg, inverse variance weighted OR 1·07 [95% CI 0·98-1·18] for α-linolenic acid). Effects were consistent across the sensitivity analyses and the FADS single-SNP analyses, suggesting that long-chain omega-3 and long-chain omega-6 fatty acid concentrations were associated with lower risk of schizophrenia (eg, OR 0·74 [95% CI 0·58-0·96] for docosahexaenoic acid) whereas short-chain omega-3 and short-chain omega-6 fatty acid concentrations were associated with an increased risk of schizophrenia (eg, OR 1·08 [95% CI 1·02-1·15] for α-linolenic acid). By contrast, estimates from the ELOVL2 single-SNP analyses were more imprecise and compatible with both risk-increasing and protective effects for each of the fatty acid measures. Multivariable Mendelian randomisation indicated that the protective effect of docosahexaenoic acid on schizophrenia persisted after conditioning on other lipids, although evidence was slightly weaker (multivariable inverse variance weighted OR 0·84 [95% CI 0·71-1·01]). INTERPRETATION: Our results are compatible with the protective effects of long-chain omega-3 and long-chain omega-6 fatty acids on schizophrenia, suggesting that people with schizophrenia might have difficulty converting short-chain polyunsaturated fatty acids to long-chain polyunsaturated fatty acids. Further studies are required to determine whether long-chain polyunsaturated fatty acid supplementation or diet enrichment might help prevent onset of schizophrenia. FUNDING: National Institute for Health Research Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jones HJ, Borges MC, Carnegie R, et al. Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study. Lancet Psychiatry. 2021. PMID: 34735824. doi:10.1016/S2215-0366(21)00286-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。